Abstract
Pruritus is one of the cardinal symptoms found in patients with leukemic cutaneous T cell lymphoma (CTCL). The nature of the pruritus experienced by CTCL patients is complex, involving different pathways and cell mediators, thus making it poorly responsive to conventional anti-itch therapies. Recent reports highlight the role of interleukin 31 (IL-31) as a novel cytokine involved in the pathogenesis of pruritus in atopic dermatitis and CTCL. Here we provide both in vivo and in vitro evidence suggesting that histone deacetylase (HDAC) inhibitors may mitigate itch through lowering of levels of IL-31-expressing T cells. Furthermore, we demonstrate that chemokine receptor type-4 (CCR4)-bearing T cells are a main source of IL-31 in CTCL, and that neutralizing the IL-31 pathway through targeting of the CCR4-expressing T cells may represent a promising therapeutic strategy for symptomatic relief in CTCL.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 1-7 |
| Number of pages | 7 |
| Journal | Clinical Immunology |
| Volume | 158 |
| Issue number | 1 |
| DOIs | |
| State | Published - May 1 2015 |
| Externally published | Yes |
Fingerprint
Keywords
- CTCL
- IL-31
- Immunotherapy
- Pruritus
ASJC Scopus subject areas
- Immunology and Allergy
- Immunology
Cite this
Improved pruritus correlates with lower levels of IL-31 in CTCL patients under different therapeutic modalities. / Cedeno-Laurent, Filiberto; Singer, Elisha M.; Wysocka, Maria; Benoit, Bernice M.; Vittorio, Carmela C.; Kim, Ellen J.; Yosipovitch, Gil; Rook, Alain H.
In: Clinical Immunology, Vol. 158, No. 1, 01.05.2015, p. 1-7.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Improved pruritus correlates with lower levels of IL-31 in CTCL patients under different therapeutic modalities
AU - Cedeno-Laurent, Filiberto
AU - Singer, Elisha M.
AU - Wysocka, Maria
AU - Benoit, Bernice M.
AU - Vittorio, Carmela C.
AU - Kim, Ellen J.
AU - Yosipovitch, Gil
AU - Rook, Alain H.
PY - 2015/5/1
Y1 - 2015/5/1
N2 - Pruritus is one of the cardinal symptoms found in patients with leukemic cutaneous T cell lymphoma (CTCL). The nature of the pruritus experienced by CTCL patients is complex, involving different pathways and cell mediators, thus making it poorly responsive to conventional anti-itch therapies. Recent reports highlight the role of interleukin 31 (IL-31) as a novel cytokine involved in the pathogenesis of pruritus in atopic dermatitis and CTCL. Here we provide both in vivo and in vitro evidence suggesting that histone deacetylase (HDAC) inhibitors may mitigate itch through lowering of levels of IL-31-expressing T cells. Furthermore, we demonstrate that chemokine receptor type-4 (CCR4)-bearing T cells are a main source of IL-31 in CTCL, and that neutralizing the IL-31 pathway through targeting of the CCR4-expressing T cells may represent a promising therapeutic strategy for symptomatic relief in CTCL.
AB - Pruritus is one of the cardinal symptoms found in patients with leukemic cutaneous T cell lymphoma (CTCL). The nature of the pruritus experienced by CTCL patients is complex, involving different pathways and cell mediators, thus making it poorly responsive to conventional anti-itch therapies. Recent reports highlight the role of interleukin 31 (IL-31) as a novel cytokine involved in the pathogenesis of pruritus in atopic dermatitis and CTCL. Here we provide both in vivo and in vitro evidence suggesting that histone deacetylase (HDAC) inhibitors may mitigate itch through lowering of levels of IL-31-expressing T cells. Furthermore, we demonstrate that chemokine receptor type-4 (CCR4)-bearing T cells are a main source of IL-31 in CTCL, and that neutralizing the IL-31 pathway through targeting of the CCR4-expressing T cells may represent a promising therapeutic strategy for symptomatic relief in CTCL.
KW - CTCL
KW - IL-31
KW - Immunotherapy
KW - Pruritus
UR - http://www.scopus.com/inward/record.url?scp=84924985426&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84924985426&partnerID=8YFLogxK
U2 - 10.1016/j.clim.2015.02.014
DO - 10.1016/j.clim.2015.02.014
M3 - Article
C2 - 25762519
AN - SCOPUS:84924985426
VL - 158
SP - 1
EP - 7
JO - Clinical Immunology
JF - Clinical Immunology
SN - 1521-6616
IS - 1
ER -